EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will host a conference call on November 3, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and recent business developments. This call is part of the company's commitment to improving therapeutics for serious eye disorders, utilizing its proprietary Durasert® technology. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, alongside its commercial products, YUTIQ® and DEXYCU®.

Positive

• Company to report third quarter financial results, which may indicate growth.
• Ongoing development of EYP-1901 for treating wet age-related macular degeneration.

Negative

• None.

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.

To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9396615. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals, Inc. 

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert^® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ^®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU^®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

Investors:

Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When will EyePoint Pharmaceuticals report its Q3 2021 financial results?

EyePoint Pharmaceuticals will report its Q3 2021 financial results on November 3, 2021.

What is EYPT's plan for its product pipeline?

EYPT is focusing on the development of its pipeline, especially EYP-1901 for wet age-related macular degeneration.

What products does EyePoint Pharmaceuticals currently have on the market?

EyePoint Pharmaceuticals currently markets YUTIQ® and DEXYCU®.